Developing selective
NLRP3 inflammasome inhibitors
for severe inflammatory diseases
Science/Technology
Our drug discovery platform is focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases including acute lung injury, ARDS, Bronchopulmonary Dysplasia, systemic sepsis, acute liver and kidney injury, and pneumonia.
Our lead candidate, AZM-152, is a small molecule, RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.
Targeting severe inflammatory diseases with significant unmet needs
Initial indications target severe inflammatory pulmonary diseases with significant unmet needs.
For many inflammatory and fibrotic lung diseases, no effective preventative or therapeutic treatments exist. With limited options for disease management, these severe and acute lung conditions exert a considerable burden on patients, families, and healthcare providers, including higher rates of mortality, longer lengths of stay in intensive care units, and life-long morbidities.
Acute Respiratory Distress syndrome
I'm a paragraph. Click here to add your own text and edit me. Let your users get to know you.
Idiopathic Pulmonary Fibrosis
Acute exacerbations of IPF
Bronchopulmonary Dysplasis
BPD is a consequence of acute injury in preterm infants.
Severe Viral Pneumoni
Including influenza A and COVID-19 infection.
We Take Pride in Our Numbers
15
Years of Experience
10K
Business Partners
25M
Products Installed
22
Countries World Wide
5
Industry Awards
Latest News
Welcome visitors to your site with a short, engaging introduction. Double click to edit and add your own text.